BofA Securities has issued a Neutral rating for HENGAN INT'L based on several positive indicators. The firm estimates that the company's 2H25 revenue will grow by 1% year-over-year to RMB10.9 billion, driven by continuous improvements across its three major business segments. Additionally, HENGAN INT'L's gross margin is expected to improve to 33.1% due to a better product mix and normalization of raw material costs in the tissue business. Furthermore, BofA predicts an 8% year-over-year increase in the company's core net profit to RMB1 billion. Despite these positive developments, the Neutral rating suggests that the analysts believe the stock is fairly valued at the elevated target price of HKD30, reflecting a cautious outlook.

Citi Research

Neutral

maintain

$27

2025-12-04

Reason

Citi Research

Price Target

$27

2025-12-04

maintain

Neutral

Reason

Citi Research raised its net profit forecasts for HENGAN INT'L for 2025-2027 by 12.1%, 18.8%, and 19.7% due to lowered SG&A/sales ratio assumptions. This adjustment reflects insights from a recent conference in China, where expectations were set for the company to recover from a low base in the second half of 2025, with a stable outlook for 2026. Consequently, Citi increased its target price from $23.1 to $27, maintaining a forward PE ratio of 11x. However, the broker kept the rating at Neutral, indicating that without significant structural improvements, HENGAN INT'L is viewed primarily as a yield-generating company with a yield of 5.4%.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01044

Unlock Now

Valuation Metrics

The current forward P/E ratio for (01044.HK) is 12.00, compared to its 5-year average forward P/E of 11.34. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

11.34

Current PE

12.00

Overvalued PE

13.08

Undervalued PE

9.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

7.11

Current EV/EBITDA

7.25

Overvalued EV/EBITDA

8.56

Undervalued EV/EBITDA

5.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.43

Current PS

1.27

Overvalued PS

1.80

Undervalued PS

1.06

Financials

AI Analysis

Annual

Quarterly

Whales Holding 01044

Trading Trends

People Also Watch

Frequently Asked Questions

What is (01044) stock price today?

The current price of 01044 is 28.94 USD — it has decreased -0.82

What is (01044)'s business?

What is the price predicton of 01044 Stock?

Wall Street analysts forecast 01044 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01044 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (01044)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (01044)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (01044). have?

(01044) has 0 emplpoyees as of March 02 2026.

What is (01044) market cap?

Today 01044 has the market capitalization of 0.00 USD.

01044 Overview